Search results
Found 59722 matches for
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim has been announced to investigate a new drug target for the treatment of schizophrenia.
Keith Hawton CBE
F - L
DSc., DM, FRCPsych, FMedSci. Keith Hawton CBE - Emeritus Director, Centre for Suicide Research
Ksenija Yeeles
S - Z
DPhil, BSc (Hons) Ksenija Yeeles - Research Fellow, SINAPPS Project Manager, Research Member of Common Room Kellogg College
Philip Wilkinson
S - Z
BMedSci BM BS (Nottingham), FRCPsych, Dip Obst (Auckland, New Zealand), Certificate in Cognitive Therapy (Oxford), ATCL, LGSMD, CELTA Philip Wilkinson - Honorary Senior Clinical Lecturer
John Gallacher
F - L
PhD AFBPsS CPsychol FFPH John Gallacher - Professor of Cognitive Health; Director, Dementias Platform UK; Director, BrainWaves study of adolescent wellbeing and mental health
John Geddes
F - L
MD FRCPsych John Geddes - WA Handley Professor of Psychiatry; Director, NIHR Oxford Health Biomedical Research Centre
Jennifer Rendell
M - R
MA(Oxon), DPhil, MBPsS Jennifer Rendell - Research Fellow & Deputy Director of Graduate Studies
Patrick Waters
S - Z
BSc PhD CSci FIBMS FRCPath Patrick Waters - Associate Professor, Co-Director Autoimmune Neurology Diagnostic Laboratory